Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease-Reference-Cited by-同舟云学术

Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease

Published:2023-08 Issue:8 Volume:37 Page:108541
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Grubić Rotkvić Petra,Ćelap Ivana,Bralić Lang Valerija,Jug Juraj,Snagić Andrea,Huljev Šipoš Ivana,Cigrovski Berković Maja

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference37 articles.

1. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways;Huynh;Pharmacol Ther,2014

2. Mechanisms in endocrinology: diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review;Levelt;Eur J Endocrinol,2018

3. Role of diabetes in congestive heart failure: the Framingham study;Kannel;Am J Cardiol,1974

4. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure;McDonagh;Eur Heart J,2021

5. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects;Lam;J Am Heart Assoc,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-dependent glucose transporter 2 inhibitors effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure;World Journal of Cardiology;2024-08-26

2. Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy;Frontiers in Endocrinology;2024-07-30

3. Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice;Diabetes, Metabolic Syndrome and Obesity;2023-08